{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T19:08:54Z","timestamp":1775761734015,"version":"3.50.1"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":2472,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1093\/annonc\/mdt054","type":"journal-article","created":{"date-parts":[[2013,5,28]],"date-time":"2013-05-28T15:08:12Z","timestamp":1369753692000},"page":"24-29","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"special_numbering":"S2","title":["Intermediate hepatocellular carcinoma: current treatments and future perspectives"],"prefix":"10.1016","volume":"24","author":[{"given":"J.-F.","family":"Dufour","sequence":"first","affiliation":[]},{"given":"I.","family":"Bargellini","sequence":"additional","affiliation":[]},{"given":"N.","family":"De Maria","sequence":"additional","affiliation":[]},{"given":"P.","family":"De Simone","sequence":"additional","affiliation":[]},{"given":"I.","family":"Goulis","sequence":"additional","affiliation":[]},{"given":"R.T.","family":"Marinho","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"issue":"4","key":"10.1093\/annonc\/mdt054_bb0010","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.jhep.2011.12.001","article-title":"EASL-EORTC Clinical Practice Guidelines: management of hepatocellular carcinoma","volume":"56","author":"European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer","year":"2012","journal-title":"J Hepatol"},{"key":"10.1093\/annonc\/mdt054_bb0015","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1055\/s-2007-1007122","article-title":"Prognosis of hepatocellular carcinoma: the BCLC staging classification","volume":"19","author":"Llovet","year":"1999","journal-title":"Semin Liver Dis"},{"issue":"2","key":"10.1093\/annonc\/mdt054_bb0020","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/hep.23725","article-title":"Loco-regional treatment of hepatocellular carcinoma","volume":"52","author":"Lencioni","year":"2010","journal-title":"Hepatology"},{"issue":"Suppl 4","key":"10.1093\/annonc\/mdt054_bb0025","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1634\/theoncologist.2010-S4-42","article-title":"Treatment of intermediate\/advanced hepatocellular carcinoma in the clinic: how can outcomes be improved?","volume":"15","author":"Lencioni","year":"2010","journal-title":"Oncologist"},{"issue":"Suppl 3","key":"10.1093\/annonc\/mdt054_bb0030","doi-asserted-by":"crossref","first-page":"S258","DOI":"10.1016\/S1590-8658(10)60514-2","article-title":"The intermediate hepatocellular carcinoma stage: should treatment be expanded?","volume":"42","author":"Piscaglia","year":"2010","journal-title":"Dig Liver Dis"},{"issue":"6","key":"10.1093\/annonc\/mdt054_bb0035","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1245\/s10434-011-1673-8","article-title":"Medium-sized (3.1\u20135.0 cm) hepatocellular carcinoma: transarterial chemoembolization plus radiofrequency ablation versus radiofrequency ablation alone","volume":"18","author":"Kim","year":"2011","journal-title":"Ann Surg Oncol"},{"issue":"13","key":"10.1093\/annonc\/mdt054_bb0040","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.3748\/wjg.v17.i13.1685","article-title":"Therapeutic options for intermediate-advanced hepatocellular carcinoma","volume":"17","author":"Zhang","year":"2011","journal-title":"World J Gastroenterol"},{"issue":"1","key":"10.1093\/annonc\/mdt054_bb0045","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1470-2045(08)70284-5","article-title":"Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis","volume":"10","author":"Mazzaferro","year":"2009","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1093\/annonc\/mdt054_bb0050","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1111\/j.1600-6143.2008.02409.x","article-title":"Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria","volume":"8","author":"Ravaioli","year":"2008","journal-title":"Am J Transplant"},{"issue":"3","key":"10.1093\/annonc\/mdt054_bb0055","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1002\/hep.22412","article-title":"Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis","volume":"48","author":"Yao","year":"2008","journal-title":"Hepatology"},{"issue":"3","key":"10.1093\/annonc\/mdt054_bb0060","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/hep.22693","article-title":"Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database","volume":"49","author":"Toso","year":"2009","journal-title":"Hepatology"},{"issue":"1","key":"10.1093\/annonc\/mdt054_bb0065","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ctrv.2011.05.002","article-title":"Locoregional radiological treatment for hepatocellular carcinoma; which, when and how?","volume":"38","author":"Meza-Junco","year":"2012","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"10.1093\/annonc\/mdt054_bb0070","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00261-008-9448-9","article-title":"Percutaneous image-guided therapy of intra-abdominal malignancy: imaging evaluation of treatment response","volume":"34","author":"Gervais","year":"2009","journal-title":"Abdom Imaging"},{"issue":"2","key":"10.1093\/annonc\/mdt054_bb0075","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1177\/107327481001700204","article-title":"Interventional radiological treatment of hepatocellular carcinoma","volume":"17","author":"Davis","year":"2010","journal-title":"Cancer Control"},{"key":"10.1093\/annonc\/mdt054_bb0080","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1634\/theoncologist.12-12-1425","article-title":"Hepatocellular carcinoma: the role of the North American GI Steering Committee Hepatobiliary Task Force and the advent of effective drug therapy","volume":"12","author":"O'Neil","year":"2007","journal-title":"Oncologist"},{"key":"10.1093\/annonc\/mdt054_bb0085","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/S0140-6736(02)08649-X","article-title":"Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial","volume":"359","author":"Llovet","year":"2002","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdt054_bb0090","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1053\/jhep.2002.33156","article-title":"Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma","volume":"35","author":"Lo","year":"2002","journal-title":"Hepatology"},{"key":"10.1093\/annonc\/mdt054_bb0095","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.ejca.2008.01.004","article-title":"Multicentre randomised phase III trial comparing tamoxifen alone or with transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma in cirrhotic patients (F\u00e9d\u00e9ration Francophone de Canc\u00e9rologie Digestive 9402)","volume":"44","author":"Doffo\u00ebl","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdt054_bb0100","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1056\/NEJM199505113321903","article-title":"A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma","volume":"332","author":"Groupe d'Etude et de Traitement du Carcinome H\u00e9patocellulaire","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdt054_bb0105","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1053\/jhep.2003.50047","article-title":"Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival","volume":"37","author":"Llovet","year":"2003","journal-title":"Hepatology"},{"issue":"1","key":"10.1093\/annonc\/mdt054_bb0110","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1148\/radiol.2241011262","article-title":"Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials","volume":"224","author":"Camm\u00e0","year":"2002","journal-title":"Radiology"},{"issue":"3","key":"10.1093\/annonc\/mdt054_bb0115","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ctrv.2010.07.006","article-title":"Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization","volume":"37","author":"Raoul","year":"2011","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"10.1093\/annonc\/mdt054_bb0120","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.jhep.2011.03.007","article-title":"EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization","volume":"55","author":"Gillmore","year":"2011","journal-title":"J Hepatol"},{"issue":"2","key":"10.1093\/annonc\/mdt054_bb0125","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1148\/radiol.11110282","article-title":"Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models","volume":"262","author":"Shim","year":"2012","journal-title":"Radiology"},{"issue":"4","key":"10.1093\/annonc\/mdt054_bb0130","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.ejca.2012.08.022","article-title":"Prospective comparison of prognostic values of modified response evaluation criteria in solid tumours with European Association for the Study of the Liver criteria in hepatocellular carcinoma following chemoembolisation","volume":"49","author":"Kim","year":"2013","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1093\/annonc\/mdt054_bb0135","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1002\/hep.24246","article-title":"Efficacy of selective transarterial chemoembolization in inducing tumor necrosis in small (<5 cm) hepatocellular carcinomas","volume":"53","author":"Golfieri","year":"2011","journal-title":"Hepatology"},{"issue":"1","key":"10.1093\/annonc\/mdt054_bb0140","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00270-009-9711-7","article-title":"Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study","volume":"33","author":"Lammer","year":"2010","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"3","key":"10.1093\/annonc\/mdt054_bb0145","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s00270-009-9750-0","article-title":"Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma","volume":"33","author":"Malagari","year":"2010","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"5","key":"10.1093\/annonc\/mdt054_bb0150","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s00270-012-0394-0","article-title":"Chemoembolization with doxorubicin-eluting beads for unresectable hepatocellular carcinoma: five-year survival analysis","volume":"35","author":"Malagari","year":"2012","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"6","key":"10.1093\/annonc\/mdt054_bb0155","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.jhep.2012.01.008","article-title":"Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolization (TACE) using DCBeads. Implications for clinical practice and trial design","volume":"56","author":"Burrel","year":"2012","journal-title":"J Hepatol"},{"key":"10.1093\/annonc\/mdt054_bb0160","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2009.09.006","article-title":"Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes","volume":"138","author":"Salem","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1093\/annonc\/mdt054_bb0165","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.3748\/wjg.14.1664","article-title":"Radioembolization for the treatment of unresectable hepatocellular carcinoma: a clinical review","volume":"14","author":"Ibrahim","year":"2008","journal-title":"World J Gastroenterol"},{"key":"10.1093\/annonc\/mdt054_bb0170","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jamcollsurg.2008.12.009","article-title":"Is selective internal radioembolization safe and effective for patients with inoperable hepatocellular carcinoma and venous thrombosis?","volume":"208","author":"Woodall","year":"2009","journal-title":"J Am Coll Surg"},{"issue":"6","key":"10.1093\/annonc\/mdt054_bb0175","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.jhep.2012.01.006","article-title":"Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma","volume":"56","author":"Park","year":"2012","journal-title":"J Hepatol"},{"issue":"6","key":"10.1093\/annonc\/mdt054_bb0180","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.jhep.2012.02.011","article-title":"TACE with or without systemic therapy?","volume":"56","author":"Dufour","year":"2012","journal-title":"J Hepatol"},{"issue":"1","key":"10.1093\/annonc\/mdt054_bb0185","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jhep.2011.12.022","article-title":"TACE treatment in hepatocellular carcinoma: what should we do now?","volume":"57","author":"Farinati","year":"2012","journal-title":"J Hepatol"},{"key":"10.1093\/annonc\/mdt054_bb0190","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/S0168-8278(09)60069-6","article-title":"Efficacy and safety of sorafenib in patients with hepatocellular carcinoma (HCC): subanalysis of sharp trial based on Barcelona Clinic Liver Cancer (BCLC) stage","volume":"50","author":"Bruix","year":"2009","journal-title":"J Hepatol"},{"key":"10.1093\/annonc\/mdt054_bb0195","doi-asserted-by":"crossref","unstructured":"RLencioniSecond interim results of the GIDEON (Global Investigation of Therapeutic DEcisions in HCC and of its treatment with sorafenib) study: Barcelona Clinic Liver Cancer (BCLC) Stage Subgroup Analysis (abstract #6500). In: ESMO-ECCO oncology meeting Stockholm; 2011.","DOI":"10.1016\/S0959-8049(11)71811-1"},{"issue":"6","key":"10.1093\/annonc\/mdt054_bb0200","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1002\/hep.24644","article-title":"Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy","volume":"54","author":"Iavarone","year":"2011","journal-title":"Hepatology"},{"key":"10.1093\/annonc\/mdt054_bb0205","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.jhep.2009.11.010","article-title":"Liver cancer: from molecular pathogenesis to new therapies: summary of the EASL single topic conference","volume":"52","author":"Dufour","year":"2010","journal-title":"J Hepatol"},{"issue":"4","key":"10.1093\/annonc\/mdt054_bb0210","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1053\/j.seminoncol.2012.05.004","article-title":"Chemoembolization for hepatocellular carcinoma","volume":"39","author":"Lencioni","year":"2012","journal-title":"Semin Oncol"},{"issue":"11","key":"10.1093\/annonc\/mdt054_bb0215","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1634\/theoncologist.2010-0180","article-title":"Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study","volume":"15","author":"Dufour","year":"2010","journal-title":"Oncologist"},{"key":"10.1093\/annonc\/mdt054_bb0220","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.4_suppl.lba154","article-title":"Sorafenib or placebo in combination with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma (HCC): Phase II, randomized, double-blind SPACE trial","author":"Lencioni","year":"2012","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1093\/annonc\/mdt054_bb0225","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.jhep.2012.07.025","article-title":"Response rate and clinical outcome of HCC after first and repeated cTACE performed \u2018on demand","volume":"57","author":"Terzi","year":"2012","journal-title":"J Hepatol"},{"issue":"1","key":"10.1093\/annonc\/mdt054_bb0230","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1148\/radiol.12112264","article-title":"Lack of response after initial chemoembolization for hepatocellular carcinoma: does it predict failure of subsequent treatment?","volume":"265","author":"Georgiades","year":"2012","journal-title":"Radiology"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419315340?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419315340?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/24\/suppl_2\/ii24\/6674907\/mdt054.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T19:07:12Z","timestamp":1668712032000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419315340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":45,"alternative-id":["S0923753419315340"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdt054","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intermediate hepatocellular carcinoma: current treatments and future perspectives","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1093\/annonc\/mdt054","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}